Breaking News

Ajinomoto, Astellas Enter ADC Technology Agreement

Will leverage AJICAP antibody-drug conjugate development and manufacturing technology as part of its CDMO business.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ajinomoto Co.

Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma Inc. for the use of AJICAP—an antibody-drug conjugate (ADC) development and manufacturing technology—as part of its CDMO business for biopharmaceutical development.  AJICAP enables precise and stable conjugation of drugs to proteins such as antibodies, helping to improve the flexibility of molecular design and the efficiency of development and manufacturing of ADCs and other next-generation biopharmaceuticals. Through t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters